資料搜尋諮詢服務
找不到您所需要的資料嗎?
我們能協助您找到最符合您研究需求的資訊
請撥打 +886-2-2799-3110
或透過電子郵件與我們聯絡 mi@hintoninfo.com
IHS_EWBIEEE xploreSTRATEGY ANALYTICSELSEVIERIHS_EWB_GF

頁面路徑選單

Regenerative Medicine Market: Information by Type, by Material, by Application, by End User, and Region—Forecast till 2027

  • LinkedIn
  • facebook
  • Twitter
出版日期:2021/08/01
頁  數:171頁
文件格式:PDF
價  格:
USD 4,450 (Single-User License)
USD 6,250 (Multi-User License)
線上訂購或諮詢

Regenerative Medicine Market—Forecast till 2027

Market Review

The regenerative medicine market is evaluated to register a substantial CAGR of 21.18% during the projected timeframe to surpass USD 152,501.51 million by 2027. Regenerative medicine is the part of medicine that creates techniques to regrow, fix or supplant harmed or unhealthy cells, organs, or tissues. Regenerative medicine incorporates the age and utilization of helpful undifferentiated cells, tissue designing, and the creation of dummy organs.
The worldwide regenerative medicine market is developing quickly and is anticipated to keep developing at a consistent rate during the review time frame. This is because of the developing commitment of existing players to make the item more viable. The inventory network investigation for the regenerative medicine market contains four significant parts, which start with the examination and item advancement followed by assembling of the items, conveyance, and deals, and finishes with post-deals administrations. Variables that impact the regenerative medicine market are expanding headway in medical services innovation, cutting edge innovation in the regenerative medicine market, expanding pervasiveness of constant infections, and expanding development in foundational microorganism innovation.
Segment Overview
The global regenerative medicine market has been divided based on type, material, application, and end-user. In terms of material type the global market has been classified into synthetic, genetically engineered, biologically derived, and others.
By Type, the global market has been dispersed into cell therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic. The application segment categorizes the global market as musculoskeletal disorders, wound care, oncology, ocular disorders, diabetes, and others.
In terms of end-user, the regenerative medicines market is divided into hospitals, specialty centers, academic & research institutes, and others.
Regional Analysis
The region-specific analysis of the global regenerative medicine market has been classified into the Americas, Europe, Asia-Pacific, and Middle East & Africa.
The Americas is likely to drive the largest market of the global regenerative medicines market during the review period. the regional market is attributed to the favorable government policies, and establishment of institutions such as the American Academy of Regenerative Medicine (AARM) and the American Board of Regenerative Medicine (ABRM), rising monetary support by investors. Europe additionally represented a huge portion of the overall industry attributable to the accomplishment of the skillet European undertakings (like CHRODIS and CHRODIS PLUS), government drives, public and private examination funders, and community-oriented logical exploration projects in the field of regenerative medicine.
Asia-Pacific is assessed to be huge in regenerative medicine treatment because of changes in medical care foundation, cross-country logical exploration projects, and preparing of scientists and youthful resources at driving establishments in the field of tissue designing and undifferentiated organism-based examination.
Major Players
The major players of the global regenerative market include Zimmer Biomet Holdings Inc. (US), AbbVie Inc. (US), Cryolife, Inc. (US), Stryker (US), Medtronic Plc (Ireland), Baxter International Inc. (US), Organogenesis Inc. (US), Ocata Therapeutics Inc. (US), Integra Lifesciences Holdings Corporation (US), Vericel Corporation (US), and Reliance Life Sciences (India)

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.


TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

2.1 SCOPE OF THE STUDY

2.2 RESEARCH OBJECTIVE

2.3 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA MINING

3.3 SECONDARY RESEARCH

3.4 PRIMARY RESEARCH

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES AND GENETIC DISORDERS

4.2.2 GROWING ADOPTION OF STEM CELL TECHNOLOGY

4.2.3 RISING PRODUCT PIPELINE OF REGENERATIVE MEDICINE

4.3 RESTRAINT

4.3.1 ETHICAL CONCERNS FOR THE USE OF EMBRYONIC STEM CELLS

4.4 OPPORTUNITY

4.4.1 IMPLICIT GUIDELINES BY THE INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH (ISSCR) RELATED TO THE EXTENDED EMBRYO CULTURE

4.5 COVID-19 IMPACT ANALYSIS

4.5.1 IMPACT ON MARKET PLAYERS

4.5.2 BRANDED AND GENERIC DRUGS IMPACT ANALYSIS

4.5.3 R&D IMPACT ANALYSIS

4.5.4 FDA POLICIES

4.5.5 OPPORTUNITY ANALYSIS

4.6 PIPELINE ANALYSIS: GLOBAL REGENERATIVE MEDICINE MARKET

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION AND SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY TYPE

6.1 OVERVIEW

6.2 CELL THERAPY

6.3 GENE THERAPY

6.4 TISSUE ENGINEERING

6.5 SMALL MOLECULE & BIOLOGIC

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY MATERIAL

7.1 OVERVIEW

7.2 SYNTHETIC

7.3 GENETICALLY ENGINEERED

7.4 BIOLOGICALLY DERIVED

7.5 OTHERS

8 GLOBAL REGENERATIVE MEDICINE MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 MUSCULOSKELETAL DISORDERS

8.3 WOUND CARE

8.4 ONCOLOGY

8.5 OCULAR DISORDERS

8.6 DIABETES

8.7 OTHERS

9 GLOBAL REGENERATIVE MEDICINE MARKET, BY END USER

9.1 OVERVIEW

9.2 HOSPITALS

9.3 SPECIALTY CENTERS

9.4 ACADEMIC & RESEARCH INSTITUTES

9.5 OTHERS

10 GLOBAL REGENERATIVE MEDICINE MARKET, BY REGION

10.1 OVERVIEW

10.2 AMERICAS

10.2.1 NORTH AMERICA

10.2.1.1 U.S

10.2.1.2 CANADA

10.2.2 LATIN AMERICA

10.3 EUROPE

10.3.1 WESTERN EUROPE

10.3.1.1 GERMANY

10.3.1.2 FRANCE

10.3.1.3 UK

10.3.1.4 ITALY

10.3.1.5 SPAIN

10.3.1.6 REST OF WESTERN EUROPE

10.3.2 EASTERN EUROPE

10.4 ASIA PACIFIC

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 AUSTRALIA

10.4.5 SOUTH KOREA

10.4.6 REST OF ASIA PACIFIC

10.5 MIDDLE EAST & AFRICA

10.5.1 MIDDLE EAST

10.5.2 AFRICA

11 COMPETITIVE LANDSCAPE

11.1 COMPETITIVEOVERVIEW

11.2 COMPETITOR DASHBOARD

11.3 MAJOR PLAYERS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.4 MAJOR GROWTH STRATEGIES IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.5 COMPETITIVE BENCHMARKING

11.6 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL REGENERATIVE MEDICINE MARKET

11.7 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.7.1 NEW PRODUCT DEVELOPMENTS/LAUNCHES

11.7.2 COLLABORATIONS/ EXPANSIONS/PARTNERSHIPS/JOINT VENTURES

11.8 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO

11.8.1 SALES & OPERATING INCOME

11.8.2 R&D EXPENDITURE

12 COMPANY PROFILES

12.1 ZIMMER BIOMET HOLDINGS INC.

12.1.1 COMPANY OVERVIEWS

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS/SERVICES OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 ABBVIE INC.

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS/SERVICES OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 CRYOLIFE, INC.

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS/SERVICES OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 STRYKER

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS/SERVICES OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 SWOT ANALYSIS

12.4.6 KEY STRATEGIES

12.5 MEDTRONIC PLC

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS/SERVICES OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 SWOT ANALYSIS

12.5.6 KEY STRATEGIES

12.6 BAXTER INTERNATIONAL INC.

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCTS OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 SWOT ANALYSIS

12.6.6 KEY STRATEGIES

12.7 ORGANOGENESIS INC.

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS/SERVICES OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 OCATA THERAPEUTICS INC.

12.8.1 COMPANY OVERVIEW

12.8.4 KEY DEVELOPMENTS

12.9 INTEGRA LIFESCIENCES HOLDINGS CORPORATION

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 SWOT ANALYSIS

12.9.6 KEY STRATEGIES

12.10 VERICEL CORPORATION

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 SWOT ANALYSIS

12.10.6 KEY STRATEGIES

12.11 RELIANCE LIFE SCIENCES

12.11.1 COMPANY OVERVIEW

12.11.2 FINANCIAL OVERVIEW

12.11.3 PRODUCTS/SERVICES OFFERED

12.11.4 KEY DEVELOPMENTS

12.11.5 SWOT ANALYSIS

12.11.6 KEY STRATEGIES

?
回上頁